Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts…
Read the full articleYou might also wanna read
IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years – Retail Calls It ‘Opportunity Of A Lifetime’
Ionis Pharmaceuticals’ Phase 3 trial, conducted in partnership with AstraZeneca, failed to meet its primary endpoint in patients with transt
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure
AstraZeneca stock fell 9% after its Wainua heart drug trial missed its primary goal, raising questions about management credibility.
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main g
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
Comments
Sign in to join the conversation.
No comments yet. Be the first.